Abstract
The present review discusses the mechanism of late stent thrombosis and its distinction from restenosis and summarizes the advisory note issued by FDA on the proper usage of different treatments available for atherosclerosis. In light of the latest developments, a plethora of new stents have been and continue to be developed globally. Hence, there is a need to review the available methodology to control their quality and to understand the delivery of drugs to the lesion. This can be achieved by systematically reviewing the novelties in each type. The article evaluates upcoming drugs, biocompatible coatings, and new concepts. We have also provided the latest update on the three new promising drug eluting stents (DES) – Medtronics Endeavor, Abbotts Xience, and Conor Medsystems CoStar. In addition, the article also summarizes other DES in horizon.
Keywords: Drug eluting stents, bare metal stents, restenosis, late stent thrombosis, polymers
Current Pharmaceutical Design
Title: Drug Eluting Stents and Beyond
Volume: 14 Issue: 21
Author(s): Ashish Rastogi and Salomon Stavchansky
Affiliation:
Keywords: Drug eluting stents, bare metal stents, restenosis, late stent thrombosis, polymers
Abstract: The present review discusses the mechanism of late stent thrombosis and its distinction from restenosis and summarizes the advisory note issued by FDA on the proper usage of different treatments available for atherosclerosis. In light of the latest developments, a plethora of new stents have been and continue to be developed globally. Hence, there is a need to review the available methodology to control their quality and to understand the delivery of drugs to the lesion. This can be achieved by systematically reviewing the novelties in each type. The article evaluates upcoming drugs, biocompatible coatings, and new concepts. We have also provided the latest update on the three new promising drug eluting stents (DES) – Medtronics Endeavor, Abbotts Xience, and Conor Medsystems CoStar. In addition, the article also summarizes other DES in horizon.
Export Options
About this article
Cite this article as:
Rastogi Ashish and Stavchansky Salomon, Drug Eluting Stents and Beyond, Current Pharmaceutical Design 2008; 14 (21) . https://dx.doi.org/10.2174/138161208785294573
DOI https://dx.doi.org/10.2174/138161208785294573 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
M-Protein-derived Conformational Peptide Epitope Vaccine Candidate against Group A Streptococcus
Current Drug Delivery Hedgehog Signaling and Urological Cancers
Current Drug Targets Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications
Current Pharmaceutical Design Chemistry, Physiology, and Pharmacology of β-Adrenergic Mechanisms in the Heart. Why are β-Blocker Antiarrhythmics Superior?
Current Pharmaceutical Design Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology Synthesis, Characterizations and Microbial Studies of Novel Mannich Products Using Multicomponent Reactions
Current Bioactive Compounds The Therapeutical Effect of Chinese Medicine for the Treatment of Atherosclerotic Coronary Heart Disease
Current Pharmaceutical Design Can microRNAs be Biomarkers or Targets for Therapy of Ischemic Coronary Artery Disease in Metabolic Syndrome?
Current Drug Targets Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Hydrogen Sulfide Regulates Vascular Inflammation and its Related Signaling Pathways
Current Signal Transduction Therapy Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews The Effect of Risk Factor Changes on Peripheral Arterial Disease and Cardiovascular Risk
Current Drug Targets - Cardiovascular & Hematological Disorders Pulmonary Hypertension: Role of Combination Therapy
Current Vascular Pharmacology Teaching a Lifestyle Intervention for Reversing Impaired Fasting Glucose, Hyperlipidemia and Obesity/Overweight to a Cohort of Local Physicians
Current Nutrition & Food Science The Frequency of Thrombotic Events Among Adults Given Antifibrinolytic Drugs for Spontaneous Bleeding: Systematic Review and Meta-Analysis of Observational Studies and Randomized Trials
Current Drug Safety MicroRNA-21 as Therapeutic Target in Cancer and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Treatment of Foot Disease in Patients with Type 2 Diabetes Mellitus using Human Umbilical Cord Blood Mesenchymal Stem Cells: Response and Correction of Immunological Anomalies
Current Pharmaceutical Design Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design